Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;66(11):e27886.
doi: 10.1002/pbc.27886. Epub 2019 Jul 26.

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort

Assaf A Barg  1   2   3 , Einat Avishai  1   2   3 , Ivan Budnik  4 , Sarina Levy-Mendelovich  1   2   3 , Tami B Barazani  2   3 , Gili Kenet  1   2   3 , Tami Livnat  1   2   3
Affiliations

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort

Assaf A Barg et al. Pediatr Blood Cancer. 2019 Nov.

Abstract

Background: Emicizumab is a bispecific antibody that bridges factor IXa and factor X to restore hemostasis in patients with hemophilia A (HA). Its efficacy and safety have been proven in multicenter trials. However, real world data regarding its use in very young children are currently lacking. Ancillary test results for monitoring emicizumab's hemostatic effect and their clinical correlations are scarce.

Methods: Children with HA and inhibitors treated by emicizumab were prospectively followed at our center. Laboratory follow-up included rotational thromboelastometry (ROTEM) and thrombin generation (TG), prior to and during treatment.

Results: Eleven children whose median age was 26 months were treated by emicizumab and followed for a median of 36 weeks. During follow-up, none experienced hemarthrosis or any other spontaneous bleeds. For 7/11 patients, emicizumab prophylaxis was sufficient to maintain hemostasis without additional supplemental therapy. Only 4/11 patients were occasionally treated with recombinant activated FVII for trauma. Two minor surgeries were safely performed without supplemental therapy while another procedure was complicated by major bleeding. TG parameters improved for all patients, correlating with their clinical status. Interestingly, the lowest TG values were obtained for patients experiencing bleeding episodes, while ROTEM parameters in all patients were close to the normal range.

Conclusions: This study confirms the safety and efficacy of emicizumab in reducing bleeds in young children with HA with inhibitors, including infants. However, surgeries warrant caution as emicizumab prophylaxis may not be sufficient for some procedures. TG may more accurately reflect the hemostasis state than ROTEM in pediatric patients treated with emicizumab.

Keywords: ROTEM; emicizumab; hemophilia A; inhibitors; thrombin generation.

PubMed Disclaimer

References

REFERENCES

    1. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe haemophilia A. Haemophilia. 2007;4(13Suppl):1-16.
    1. Manco-Johnson MJ, Soucie JM, Gill JC. Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129:2368-2374.
    1. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood. 2014;124:3365-3372.
    1. Abbonizio F, Giampaolo A, Coppola A; Italian Association of Haemophilia Centres, Arcieri R, Hassan HJ. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia. 2014;20:e243-e250.
    1. Leissinger CA, Singleton T, Kruse-Jarres R. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Blood. 2015;126:153-159.

Publication types

LinkOut - more resources